IBA reports H1 2026 financial turnaround with 9.3 million euro net profit

IBA returned to profitability in the first half of 2026, reporting a net income of 9.3 million euros compared to a 2.6 million euro loss in the same period last year. The improvement is driven by a higher gross margin of 33.7% and a recovery in the Proton Therapy segment. Results align with previous company forecasts.